Loading...
Apatinib Plus Temozolomide for Recurrent Glioblastoma: An Uncontrolled, Open-Label Study
OBJECTIVE: This study aimed to determine the efficacy and tolerability of apatinib plus dose-dense temozolomide (TMZ) as first-line treatment for recurrent glioblastoma (rGBM). METHODS: Patients with rGBM were enrolled in this study. Patients were subjected to concurrent treatment of apatinib (500 m...
Saved in:
| Published in: | Onco Targets Ther |
|---|---|
| Main Authors: | , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
Dove
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6899067/ https://ncbi.nlm.nih.gov/pubmed/31819537 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S226804 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|